What key areas should investors focus on during MedTech due diligence?

Investors conducting due diligence in MedTech should prioritize the scientific and clinical validity of the device, ensuring it addresses a real problem with a sound solution. They must also evaluate the regulatory pathway and reimbursement strategies, considering frameworks such as the FDA's eSTAR program for submission. Finally, assessing the engineering durability, which includes cybersecurity, is crucial for long-term viability.

Why is due diligence particularly important in neurotech investments?

Due diligence in neurotech is especially critical because the field often generates significant public interest, which can sometimes outpace scientific validation. Investors must carefully differentiate between speculative claims and genuine technological advancements, focusing on robust evidence and adherence to standards like ISO 14971 for risk management. This ensures investments are directed towards truly impactful and ethically sound innovations.

How does cybersecurity relate to MedTech investment diligence?

Cybersecurity is a vital component of MedTech investment diligence, falling under the umbrella of engineering durability. A device's vulnerability to cyber threats can lead to significant financial repercussions, data breaches, and even patient harm, making adherence to cybersecurity frameworks like NIST 800-53 essential. Proactive cybersecurity measures can prevent costly reworks—potentially saving a company $500,000—and are critical for ensuring the safety and reliability of networked medical devices in an increasingly connected world.

Science Before Hype in MedTech Investing with Varun…

Science Before Hype in MedTech Investing with Varun Turlapati of Chaanakya Capital

With Varun Turlapati - Early-stage MedTech gets riskier when investors confuse a compelling story with a credible device. Stronger diligence starts by testing whether the science is real, whether clinicians would actually use the product, and whether the company has thought seriously about regulatory fit, reimbursement logic, and engineering

By Christian Espinosa, MBA, CISSP

Founder & CEO · Blue Goat Cyber

Listen now

Episode breakdown

Key takeaways

Early-stage MedTech investment requires robust diligence to differentiate compelling narratives from credible devices.
Diligence should verify the scientific validity of the device and its practical utility for clinicians.
Regulatory fit, reimbursement strategy, and engineering durability are critical considerations for MedTech investments.
Neurotech, despite public interest, necessitates rigorous diligence to distinguish breakthroughs from unsubstantiated claims.
Cybersecurity is an essential hardening issue in MedTech, particularly within neurotech.
Specialist funds employ distinct operational models for MedTech investment. Investments in MedTech should consider engineering durability, especially in the context of cybersecurity.

Early-stage MedTech gets riskier when investors confuse a compelling story with a credible device. Stronger diligence starts by testing whether the science is real, whether clinicians would actually use the product, and whether the company has thought seriously about regulatory fit, reimbursement logic, and engineering durability.

That framework becomes even more important in neurotech, where public fascination can outrun the evidence base and where the difference between a breakthrough and a weak claim is often diligence quality.

Frequently asked questions

Bring this work to your device

Need help with fda premarket cybersecurity?

Blue Goat Cyber delivers fda premarket cybersecurity services for medical device manufacturers - from threat modeling to FDA-ready reports.

FDA Premarket Cybersecurity Services

Science Before Hype in MedTech Investing with Varun Turlapati of Chaanakya Capital

Episode breakdown

Key takeaways

Read the conversation

Frequently asked questions

Need help with fda premarket cybersecurity?

Navigating U.S. Market Entry for MedTech Developers with JJ Amell

De-Risking Product Decisions in MedTech Startups with Brent Lavin of Ironwood MedTech Partners

Why Clinical Trials Are the Most Expensive Capital Outlay for Startups with Rob Bedford, CEO of Franklyn Health

Edge Cases, Alarm Fatigue, and Why AI Cannot Replace Clinical Judgment with Brandon Fertig, Senior Manager at Philips Healthcare

Get FDA cleared without the cybersecurity headaches.

Science Before Hype in MedTech Investing with Varun Turlapati of Chaanakya Capital

Episode breakdown

Key takeaways

Read the conversation

Frequently asked questions

Need help with fda premarket cybersecurity?

Keep listening

Navigating U.S. Market Entry for MedTech Developers with JJ Amell

De-Risking Product Decisions in MedTech Startups with Brent Lavin of Ironwood MedTech Partners

Why Clinical Trials Are the Most Expensive Capital Outlay for Startups with Rob Bedford, CEO of Franklyn Health

Edge Cases, Alarm Fatigue, and Why AI Cannot Replace Clinical Judgment with Brandon Fertig, Senior Manager at Philips Healthcare

Get FDA cleared without the cybersecurity headaches.